Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and - Scorecard - MDSpire

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and

  • By

  • Wei Zhang

  • Haowen Wu

  • Langkun Wang

  • Hang Xu

  • Tianhai Lin

  • Ping Tan

  • Peng Zhang

  • Xiaonan Zheng

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Antibody-Drug Conjugates in the Treatment of Locally Advanced and Metastatic Urothelial Carcinoma: A Comprehensive Review

At a Glance

CategoryDetail
Condition
Key MechanismsAntibody-drug conjugates (ADCs) target specific proteins on tumor cells, such as nectin-4 and trop-2, enhancing drug delivery while minimizing damage to healthy tissues.
Target Population
Care Setting

Key Highlights

  • Platinum-based chemotherapy has been the standard of care, but many patients are cisplatin-ineligible. Objective response rates for immune checkpoint inhibitors in unselected populations are around 20% (reference needed).
  • Antibody-drug conjugates like enfortumab vedotin and sacituzumab govitecan show promise in treatment, with data from interventional trials and observational studies quantifying outcomes.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • R
      • e
      • g
      • u
      • l
      • a
      • r
      • a
      • s
      • s
      • e
      • s
      • s
      • m
      • e
      • n
      • t
      • o
      • f
      • t
      • r
      • e
      • a
      • t
      • m
      • e
      • n
      • t
      • -
      • r
      • e
      • l
      • a
      • t
      • e
      • d
      • a
      • d
      • v
      • e
      • r
      • s
      • e
      • e
      • v
      • e
      • n
      • t
      • s
      • a
      • n
      • d
      • c
      • l
      • i
      • n
      • i
      • c
      • a
      • l
      • e
      • n
      • d
      • p
      • o
      • i
      • n
      • t
      • s
      • s
      • u
      • c
      • h
      • a
      • s
      • o
      • v
      • e
      • r
      • a
      • l
      • l
      • s
      • u
      • r
      • v
      • i
      • v
      • a
      • l
      • a
      • n
      • d
      • p
      • r
      • o
      • g
      • r
      • e
      • s
      • s
      • i
      • o
      • n
      • -
      • f
      • r
      • e
      • e
      • s
      • u
      • r
      • v
      • i
      • v
      • a
      • l
      • ,
      • i
      • d
      • e
      • a
      • l
      • l
      • y
      • e
      • v
      • e
      • r
      • y
      • 3
      • m
      • o
      • n
      • t
      • h
      • s
      • .

      Risks

        Patient & Prescribing Data

        Adult patients with locally advanced or metastatic urothelial carcinoma.

        Antibody-drug conjugates are being evaluated for their efficacy and safety in both monotherapy and combination regimens.

        Clinical Best Practices

        • best_practice

        Related Resources & Content

        Original Source(s)

        Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and

        • by Wei Zhang, Haowen Wu, Langkun Wang, Hang Xu, Tianhai Lin, Ping Tan, Peng Zhang, Xiaonan Zheng

        • June 1, 2026

        Related Content

        Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

        Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

        Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors